Compare · BEAT vs BSX
BEAT vs BSX
Side-by-side comparison of Heartbeam Inc. (BEAT) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEAT and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 2630.9x BEAT ($24.3M).
- BEAT has been more active in the news (11 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 10 for BEAT).
- Company
- Heartbeam Inc.
- Boston Scientific Corporation
- Price
- -
- -
- Market cap
- $24.3M
- $63.97B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 5
- Recent ratings
- 10
- 25
Heartbeam Inc.
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BEAT
- HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
- SEC Form 4 filed by Heartbeam Inc.
- SEC Form 4 filed by Heartbeam Inc.
- SEC Form 4 filed by Heartbeam Inc.
- SEC Form 4 filed by Heartbeam Inc.
- SEC Form 4 filed by Heartbeam Inc.
- SEC Form 4 filed by Heartbeam Inc.
- Commercial Orders, FDA Firepower and Crypto Momentum
- HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment
- HeartBeam downgraded by H.C. Wainwright
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events